ETS transcription factor ELK2B, pseudogene (ELK2BP)

ELK2BP (ETS transcription factor ELK2B, pseudogene) is officially classified as a pseudogene, meaning it is a DNA sequence similar to a gene but is generally non-functional and not expressed as a functional protein product[1]. While it is related to the ETS family of transcription factors—which are involved in regulation of cellular differentiation, proliferation, and other important processes—the ELK2BP pseudogene itself does not function as a transcription factor, does not encode a functional protein, and is not considered a therapeutic target[1]. There is no evidence linking ELK2BP specifically to any drug interactions, disease relevance, or biomarker roles. Supporting Details and Context - The ETS (E26 Transformation-Specific) family of transcription factors is large and functionally important, known for regulating gene expression related to cell proliferation, differentiation, migration, and cancer[2][3][4][5]. - The ELK subset of ETS transcription factors (ELK1, ELK3, ELK4) has been studied in oncogenesis and various signaling pathways[5]; however, ELK2BP is not an active member of this family. - Pseudogenes such as ELK2BP are former genes that have typically accumulated mutations rendering them non-functional. They do not participate in signal transduction or other biological roles like their protein-coding relatives. - There are no known reports of drugs, biomarkers, or diseases specifically associated with ELK2BP[1]. Critical note: This name (ELK2BP, ELK2.2) refers to a pseudogene, not to a canonical drug target, receptor, or enzyme. It is not considered actionable in drug discovery or therapeutic contexts, and should not be mistaken for functional ETS transcription factor family members[1]. If you need information on functional ETS transcription factors (such as ELK1, ELK3, ELK4) or the broader ETS family and their relevance in cancer or drug discovery, that can be provided, but ELK2BP is not itself a drug target.

Other names

ELK2.2ELK2BP